Why the study?
Acute management of pediatric supraventricular tachycardia can be challenging because the precise underlying mechanism is often unknown.
Do various antiarrhythmic drugs improve response rates in pediatric patients with supraventricular tachycardia without structural heart disease?
Do various antiarrhythmic drugs improve response rates in pediatric patients with supraventricular tachycardia without structural heart disease?
In pediatric patients with SVT without structural heart disease, various antiarrhythmic drugs and their combinations show varying efficacy, highlighting the need for individualized treatment based on patient history.
Answers are grounded in this paper and cite their sources.
Drug-specific response rates support individualized selection in pediatric SVT; high heterogeneity leaves optimal regimens open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hashim et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: